Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | CCL2 | P13500 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20085933 | 0.85 | EGLN2 (0.39) | MRGPRX4P4HTM | |
| SCHEMBL20249195 | 0.83 | NUDT1 (0.41) | MRGPRX4P4HTM | |
| SCHEMBL20249230 | 0.82 | POLB (0.33) | MRGPRX4 | |
| SCHEMBL22043316 | 0.82 | CACNA1I (0.40) | PTGS2CYP3A4MRGPRX4 | |
| SCHEMBL20089414 | 0.80 | CHRNB2 (0.41) | BRD4CCL2 | |
| SCHEMBL12710188 | 0.79 | NQO1 (0.50) | — | |
| SCHEMBL30946567 | 0.79 | MCHR1 (0.46) | PTGS2BRD4CCL2SYKMCHR1 | |
| SCHEMBL30699249 | 0.79 | KDM4E (0.40) | BRD4CCL2MCHR1BACE1 | |
| SCHEMBL16331935 | 0.79 | MCHR1 (0.46) | PTGS2BRD4CCL2SYKMCHR1 | |
| SCHEMBL625665 | 0.79 | KDM4E (0.40) | BRD4CCL2MCHR1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11530194-B2 | Amide compounds and method for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-20210214342-A1 | AMIDE COMPOUNDS AND METHOD FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2021-07-15 | — | — | US | disclosed |
| US-10947216-B2 | Amide compounds and method for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-10414753-B2 | Amide compounds and method for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-20180111917-A1 | AMIDE COMPOUNDS AND METHOD FOR MAKING AND USING | MIDCAP FINANCIAL TRUST | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10947216-B2 | Amide compounds and method for making and using | IRAK1, IRAK2, IRAK3 | PTGS2 1496/4885BRD4 103/4885CCL2 328/4885 |
| US-20180111917-A1 | AMIDE COMPOUNDS AND METHOD FOR MAKING AND USING | IRAK1, IRAK2, IRAK3 | PTGS2 1496/4885BRD4 103/4885CCL2 328/4885 |
| US-10414753-B2 | Amide compounds and method for making and using | IRAK1, IRAK2, IRAK3 | PTGS2 1496/4885BRD4 103/4885CCL2 328/4885 |
| US-11530194-B2 | Amide compounds and method for making and using | IRAK1, IRAK2, IRAK3 | PTGS2 1496/4885BRD4 103/4885CCL2 328/4885 |
| US-20210214342-A1 | AMIDE COMPOUNDS AND METHOD FOR MAKING AND USING | IRAK1, IRAK2, IRAK3 | PTGS2 1496/4885BRD4 103/4885CCL2 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.